Banerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO 2022;Abstract 529MO.
DiSilvestro P et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial. ESMO 2022;Abstract 517O.
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
Gonzalez Martin AJ et al. PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. ESMO 2022;Abstract 530P.
Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29. Abstract
Kim SK et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 2022;165(2):385-92. Abstract
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.
Lorusso D et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205. ASCO 2022;Abstract 5507.
Maio M et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33(9):929-38. Abstract
Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract
Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.
Makker V et al. Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. ESMO 2022;Abstract 525MO.
Matulonis U et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA4.
Matulonis UA et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR-alpha) expression: Characterization of antitumor activity in the SORAYA study. ASCO 2022;Abstract 5512.
Mauricio D et al. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. SGO 2022;Abstract 46.
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract
Monk BJ et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. ASCO 2022;Abstract LBA5500.
Monk B et al. Patient-reported outcomes from the Phase 3 randomized, double-blind, KEYNOTE-826 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. SGO 2022;Abstract 23.
Oaknin A et al Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. ASCO 2022;Abstract 5509.
O’Malley D et al. Mirvetuximab soravtansine and bevacizumab in folate receptor alpha-positive ovarian cancer: Efficacy in patients with and without prior bevacizumab. IGCS 2022;Abstract O011/#496.
Oza AM et al. Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. ESMO 2022;Abstract 518O.
Penson R et al. Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer. SGO 2022;Abstract 26.
Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov 38 trial. ESMO 2021;Abstract LBA33.
Ray-Coquard IL et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ESMO 2022;Abstract LBA29.
Richardson D et al. Updated results from the Phase 1 expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 76.
Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 5558.
Tewari KS et al. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826. ASCO 2022;Abstract 5506.
Tewari KS et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386(6):544-55. Abstract
Vergote IB et al. Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. ESMO Virtual Plenary 2022;Abstract VP2-2022.
You B et al. Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial. AACR 2022;Abstract CT005.